The story of Viagra and its originator, copyright, presents a complex picture for prospective investors. While the revolutionary drug initially generated enormous earnings, its exclusivity has ended, leading to rival alternatives flooding the arena. This reduction in cost presents a significant challenge for copyright and any company considering a